Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial

Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial

Background: Risedronate increases bone mineral density (BMD) and reduces fracture risk, but treatment response may depend on the baseline state of bone turnover. Data regarding the selection of therapeutic drugs or the prediction of therapeutic effects with baseline levels of bone turnover markers (...

Full description

Bibliographic Details
Main Authors: Taro Mawatari, Satoshi Ikemura, Gen Matsui, Takahiro Iguchi, Hiroaki Mitsuyasu, Shinya Kawahara, Masayuki Maehara, Ryoichi Muraoka, Yukihide Iwamoto, Yasuharu Nakashima
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Bone Reports
Subjects:
Bone turnover markers
Bone isoforms of alkaline phosphatase
C-telopeptide of type I collagen
Tartrate-resistant acid phosphatase-5b
Risedronate
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187220300358

Internet

http://www.sciencedirect.com/science/article/pii/S2352187220300358

Similar Items